| Paul Kelly O'neill, RPH | |
|
2791 Dakota Ave S, Huron, SD 57350-4411 | |
| (605) 353-9513 | |
| (605) 353-9515 |
| Full Name | Paul Kelly O'neill |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 2791 Dakota Ave S, Huron, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013339118 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 5540 (New Mexico) | Secondary |
| 183500000X | Pharmacist | R5306 (South Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Paul Kelly O'neill, RPH 2791 Dakota Ave S, Huron, SD 57350-4411 Ph: (605) 353-9513 | Paul Kelly O'neill, RPH 2791 Dakota Ave S, Huron, SD 57350-4411 Ph: (605) 353-9513 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.
ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.
A new debate in the open access journal PLoS Medicine questions whether all African children with fever should be treated presumptively with antimalarial drugs, or if treatment should wait until laboratory tests confirm malarial infection.
› Verified 8 days ago
Angela Le, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Dakota Ave N Ste A, Huron, SD 57350 Phone: 605-352-9222 | |
Ms. Melissa Kay Rex, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2791 Dakota Ave S, Huron, SD 57350 Phone: 605-353-9513 | |
Megan Sue Nelson, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1950 Dakota Ave S, Huron, SD 57350 Phone: 605-352-6496 | |
Lea Telkamp, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 88 3rd St Se Ste P, Huron, SD 57350 Phone: 605-663-1001 | |
Mrs. Ann Marie Cruse, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1950 Dakota Ave S, Huron, SD 57350 Phone: 605-352-6496 Fax: 605-352-7519 | |
Dr. Joshua L Morrison, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2791 Dakota Ave S, Huron, SD 57350 Phone: 605-353-9513 Fax: 605-353-9515 |